The aim of the current study was to determine the effect of acetaminophen on ischemia- reperfusion injery in patients with ST segment elevation acute myocardial infarction(STEMI) treated by primary percutaneous coronary intervention (pPCI). This study is a double blind randomized clinical trial which its population is all of the patients with STEMI diagnosis.
Inclusion criteria include: patient willingness to take part in the study, informed consent, age above 20 and below 65 years and include all patients with STEMI.
Exclusion criteria included a history of kidney and liver disease, acute hepatitis, asthma, pregnancy, cardiac output less than 30%, history of heart failure, and consumption of acetaminophen, warfarin, salicylates, barbiturates, carbamazepine, hydantoin and rifampin, rifabutin, isoniazid, alcohol, and antioxidants drugs. A total of 60 patients will be selected among those eligible. Patients were randomly divided in two groups. Before the angioplasty case group receive 1 grams of paracetamol, and then patient hemodynamic parameters and blood biomarker will be checked before and 6 hours after p PCI. Also in order to measure the amount of cellular damage, blood sample will be taken from the coronary of heart before and after p PCI, and in order to evaluate the levels of homocysteine, glutathione and malondialdehyde serum of blood will be kept at -20 C.